Kim Kramer

List of Publications by Year
in descending order

65 papers	3,500 citations	201674 27 h-index	144013 57 g-index
67 all docs	67 docs citations	67 times ranked	4193 citing authors

#	Article	IF	Citations
1	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
2	Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission. Journal of Clinical Oncology, 2012, 30, 3264-3270.	1.6	215
3	Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. Journal of Neuro-Oncology, 2010, 97, 409-418.	2.9	208
4	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncology, The, 2018, 19, 1040-1050.	10.7	201
5	Phase II Trial of the Anti-G_{D2}Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma. Journal of Clinical Oncology, 2001, 19, 4189-4194.	1.6	192
6	Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients. Journal of Clinical Oncology, 2001, 19, 3397-3405.	1.6	159
7	Neuroblastoma metastatic to the central nervous system. Cancer, 2001, 91, 1510-1519.	4.1	131
8	Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 5271-5276.	1.6	121
9	Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131-I-3F8. Journal of Clinical Oncology, 2007, 25, 5465-5470.	1.6	121
10	Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with Î²-Glucan for High-Risk Neuroblastoma in Second or Later Remission. Clinical Cancer Research, 2014, 20, 1375-1382.	7.0	118
11	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230.	1.0	114
12	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26409.	1.5	66
13	Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Medical and Pediatric Oncology, 2000, 35, 468-474.	1.0	64
14	Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e330-e336.	10.7	59
15	Oral Etoposide for Refractory and Relapsed Neuroblastoma. Journal of Clinical Oncology, 1999, 17, 3221-3225.	1.6	55
16	Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of Î±-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2. Clinical Cancer Research, 2004, 10, 6985-6992.	7.0	52
17	Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_{D2}immunotherapy and isotretinoin: a prospective Phase II study. OncoImmunology, 2015, 4, e1016704.	4.6	52
18	Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget, 2016, 7, 4155-4166.	1.8	51

#	Article	IF	Citations
19	Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology, 2018, 7, e1461305.	4.6	49
20	A phase II study of radioimmunotherapy with intraventricular ¹³¹Iâ€3F8 for medulloblastoma. Pediatric Blood and Cancer, 2018, 65, e26754.	1.5	46
21	Targeted radioimmunotherapy for leptomeningeal cancer using131I-3F8. Medical and Pediatric Oncology, 2000, 35, 716-718.	1.0	43
22	A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: <scp>L</scp>ongâ€term progressionâ€free survival of patients with resistant neuroblastoma. International Journal of Cancer, 2017, 140, 480-484.	5.1	41
23	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 2017, 12, e0178593.	2.5	38
24	Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro-Oncology, 2022, 24, 1763-1772.	1.2	37
25	MONOCLONAL ANTIBODY-BASED THERAPY OF NEUROBLASTOMA. Hematology/Oncology Clinics of North America, 2001, 15, 853-864.	2.2	36
26	Differential impact of highâ€dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer, 2010, 116, 3054-3060.	4.1	36
27	Striking dichotomy in outcome of MYCNâ€amplified neuroblastoma in the contemporary era. Cancer, 2014, 120, 2050-2059.	4.1	36
28	Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 194-196.	1.0	33
29	Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies. Pediatric Blood and Cancer, 2014, 61, 1590-1592.	1.5	29
30	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine, 2019, 60, 1794-1801.	5.0	29
31	Central nervous system relapse of rhabdomyosarcoma. Pediatric Blood and Cancer, 2018, 65, e26710.	1.5	27
32	Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer, 2005, 103, 858-862.	4.1	26
33	Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving antiâ€G_{D2} 3F8 monoclonal antibody. Cancer, 2013, 119, 2789-2795.	4.1	26
34	Oral Topotecan for Refractory and Relapsed Neuroblastoma: A Retrospective Analysis. Journal of Pediatric Hematology/Oncology, 2003, 25, 601-605.	0.6	25
35	Treatment and outcome of adultâ€onset neuroblastoma. International Journal of Cancer, 2018, 143, 1249-1258.	5.1	23
36	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. Journal of Neuro-Oncology, 2015, 123, 245-249.	2.9	22

#	Article	IF	Citations
37	Synovial sarcoma mimicking desmoplastic small round-cell tumor: Critical role for molecular diagnosis. , 1999, 32, 97-101.		21
38	Curability of Recurrent Disseminated Disease After Surgery Alone for Local-Regional Neuroblastoma Using Intensive Chemotherapy and Anti-GD2 Immunotherapy. Journal of Pediatric Hematology/Oncology, 2003, 25, 515-519.	0.6	21
39	Highâ€dose carboplatinâ€“irinotecanâ€“temozolomide: Treatment option for neuroblastoma resistant to topotecan. Pediatric Blood and Cancer, 2011, 56, 403-408.	1.5	21
40	Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. Journal of Neuro-Oncology, 1997, 35, 101-112.	2.9	18
41	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of Nuclear Medicine, 2016, 57, 231-237.	5.0	17
42	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. Journal of Neuro-Oncology, 2019, 143, 101-106.	2.9	17
43	Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 849-854.	0.8	16
44	Osteochondroma in longâ€term survivors of highâ€risk neuroblastoma. Cancer, 2015, 121, 2090-2096.	4.1	15
45	Detection of neuroblastoma in bone marrow by immunocytology: Is a single marrow aspirate adequate?. , 1999, 32, 84-87.		12
46	Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 334-342.	6.4	11
47	MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. Oncotarget, 2017, 8, 95293-95302.	1.8	10
48	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamabâ€”pharmacokinetic modeling to optimize therapeutic index. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1166-1177.	6.4	9
49	Reducedâ€dose craniospinal irradiation for central nervous system relapsed neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28364.	1.5	7
50	Phase I Trial of Oral Yeast-Derived Î²-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers, 2021, 13, 6265.	3.7	6
51	Favorable-Biology Neuroblastoma Presenting With Leptomeningeal Metastases?. Journal of Pediatric Hematology/Oncology, 2004, 26, 703-705.	0.6	4
52	Establishing successful cerebrospinal fluid flow for radioimmunotherapy. Journal of Neurosurgery: Pediatrics, 2012, 9, 316-319.	1.3	4
53	Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7-H3 radioimmunotherapy. Journal of Neuro-Oncology, 2019, 144, 227-229.	2.9	4
54	Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular Radioimmunotherapy. Journal of Nuclear Medicine, 2020, 61, 662-664.	5.0	3

#	Article	IF	Citations
55	Reply to K. Satharasinghe et al. Journal of Clinical Oncology, 2009, 27, e235-e235.	1.6	2
56	A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy. Pediatric Blood and Cancer, 2009, 53, 1340-1342.	1.5	2
57	EPCT-21. NEXT-GENERATION SEQUENCING OF CEREBROSPINAL FLUID FOR CLINICAL MOLECULAR DIAGNOSTICS IN ADOLESCENT AND YOUNG ADULT (AYA) BRAIN TUMOR PATIENTS. Neuro-Oncology, 2021, 23, i51-i51.	1.2	2
58	Antibody-based diagnostic and therapeutic innovations for human cancer. Comprehensive Therapy, 2001, 27, 183-194.	0.2	1
59	Rare Primary Central Nervous System Tumors Encountered in Pediatrics. Journal of Child Neurology, 2016, 31, 1394-1398.	1.4	1
60	Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 2411-2414.	4.2	1
61	N7: A novel multiâ€modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230.	1.0	1
62	Management of Neurologic Complications. , 2005, , 213-222.		1
63	Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device. Journal of Neuro-Oncology, 2022, 157, 457-463.	2.9	1
64	Radioimmunotherapy of Neuroblastoma. Medical Radiology, 2013, , 629-638.	0.1	0
65	Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastomaâ€"A New Standard of Care?. JAMA Oncology, 2022, 8, 301.	7.1	0